PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy (TARE-05-073M)

This study has been completed.
Sponsor:
Information provided by:
Umeå University
ClinicalTrials.gov Identifier:
NCT00390598
First received: October 19, 2006
Last updated: March 23, 2011
Last verified: December 2008

October 19, 2006
March 23, 2011
September 2005
December 2006   (final data collection date for primary outcome measure)
Efficacy of large bowel cleansing as assessed by the physician performing the colonoscopy. Two validated scoring systems are used.
Same as current
Complete list of historical versions of study NCT00390598 on ClinicalTrials.gov Archive Site
  • The subjective grading of patients on ease of taking the large bowel preparation treatment.
  • Frequency of not completed large bowel preparation treatment.
  • Frequency of abdominal symptoms due to bowel preparation treatment.
  • Frequency of incomplete colonoscopies with insufficient view leading to a repeated colonoscopy due to low diagnostic quality at the first attempt.
  • Costs of large bowel cleansing.
  • Frequency of abdominal symptoms that start after onset of large bowel preparation treatment and that persists one week after the colonoscopy.
Same as current
Not Provided
Not Provided
 
PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy
A Single Blind, Single Centre, Parallel Group, Randomized Controlled Trial Comparing PEG Solution (Laxabon®) 4L Versus Senna Glycoside (Pursennid® Ex-Lax) 36mg and PEG Solution (Laxabon®) 2L for Large Bowel Cleansing Prior to Colonoscopy

The trial compares Laxabon® 4L versus Pursennid® Ex-Lax 36mg and 2L Laxabon® for large bowel cleansing prior to colonoscopy allocating patients planned for colonoscopy to one of the two cleansing regimens.

Effective large bowel cleansing prior to colonoscopy is still not achieved in all cases that undergo the procedure. The use of balanced electrolyte-polyethylene glycol (PEG) solution have improved the cleansing results and shortened the time needed for preparing the bowel. The problem with using PEG solution alone is the relatively large volume of the solution that the patients need to drink. The recommendation is to drink the solution until diarrhea fluid is clear and often 4 L or more is needed. Many patients refuse to drink the sufficient volume needed to get a clean colon. The large volume load can be a risk to patients suffering from renal and/or heart insufficiency.

Good results of bowel cleansing have also been reported with sodium phosphate solution or tablets. The fluid volume needed to drink along with sodium phosphate is generally no problem but this regimen causes electrolyte disturbances that usually are subclinical and of no significance but in patients with renal or heart insufficiency the sodium phosphate is contraindicated due to the risk of serious electrolyte disturbances.

Several combinations of stimulant laxatives with PEG solution have been tested before and the actual combination has been compared in one randomized study(1). Low-volume PEG plus sennosides preparation was better tolerated but it was not as effective as standard large-volume PEG.

PEG solution (Laxabon®) 4L is used for large bowel cleansing in many centers in Sweden and is the standard regimen used in our colonoscopy unit. In this study we compare this standard regimen with senna glycoside (Pursennid® Ex-Lax) 36mg (tablets) taken orally in the night before the colonoscopy and 2L Laxabon® solution orally starting to drink the solution four hours prior to the colonoscopy.

The result of large bowel cleansing is evaluated during the colonoscopy according to two separate validated scoring methods (Aronchick and Ottawa scores). Abdominal symptoms, discomfort, subjective grading of how hard/easy it was to complete the cleansing program and extra costs are evaluated with questionnaires.

Interventional
Phase 2
Phase 3
Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind
Primary Purpose: Treatment
Colonoscopy
  • Drug: PEG (solution given 4 L)
    Other Name: Laxabon (R) =PEG solution
  • Drug: senna glycoside 36 mg and PEG (solution given 2 L)
    Other Names:
    • Pursennid ExLax (R)= senna
    • Laxabon (R)= PEG solution
  • Active Comparator: senna 36 mG + PEG 2L
    Bowel preparation with senna tablets 36 mG and PEG 2L prior to colonoscopy.
    Intervention: Drug: senna glycoside 36 mg and PEG (solution given 2 L)
  • Active Comparator: 4 L PEG
    Bowel preparation with 4 L PEG prior to colonoscopy.
    Intervention: Drug: PEG (solution given 4 L)

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
490
December 2006
December 2006   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patient scheduled to undergo elective complete colonoscopy as an outpatient
  • Age 18 or older
  • The patient gives written informed consent and can understand the information given
  • The patient can participate only once in the study

Exclusion Criteria:

  • Earlier resection of the large bowel or rectum
  • Active known colitis
  • Ileus or gastro-intestinal obstruction
Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Sweden
 
NCT00390598
TARE-05-073M
Not Provided
Markku Haapamäki, Umea University
Umeå University
Not Provided
Study Chair: Peter Naredi, MD, PhD Umeå University
Principal Investigator: Markku M Haapamaki, MD, PhD Umeå University
Umeå University
December 2008

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP